Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Karen R Broder"'
Autor:
Kenneth E. Schmader, Christine K. Liu, Brendan Flannery, Wes Rountree, Heidi Auerbach, Elizabeth D. Barnett, Elizabeth P. Schlaudecker, Christopher A. Todd, Marek Poniewierski, Mary A. Staat, Theresa Harrington, Rongxia Li, Karen R. Broder, Emmanuel B. Walter
Publikováno v:
Immunity & Ageing, Vol 20, Iss 1, Pp 1-11 (2023)
Abstract Background Adjuvanted inactivated influenza vaccine (aIIV) and high-dose inactivated influenza vaccine (HD-IIV) are U.S.-licensed for adults aged ≥ 65 years. This study compared serum hemagglutination inhibition (HAI) antibody titers for t
Externí odkaz:
https://doaj.org/article/275af69609234cc6b4651fc11dd8d745
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 4, Pp 391-400 (2017)
Introduction: Varicella vaccines are highly effective at preventing disease, but varicella may occur among vaccinated persons (termed breakthrough varicella). Breakthrough varicella is generally mild, but severe cases have been reported. The objectiv
Externí odkaz:
https://doaj.org/article/350580132c194b359d56320dcef9acd4
Autor:
Zhao-Hua Zhou, Margaret M. Cortese, Jia-Long Fang, Robert Wood, Donna S. Hummell, Kimberly A. Risma, Allison E. Norton, Mark KuKuruga, Susan Kirshner, Ronald L. Rabin, Cyrus Agarabi, Mary A. Staat, Natasha Halasa, Russell E. Ware, Anna Stahl, Maureen McMahon, Peter Browning, Panagiotis Maniatis, Shanna Bolcen, Kathryn M. Edwards, John R. Su, Sai Dharmarajan, Richard Forshee, Karen R. Broder, Steven Anderson, Steven Kozlowski
BackgroundThe mechanism for anaphylaxis following mRNA COVID-19 vaccination has been widely debated; understanding this serious adverse event is important for future vaccines of similar design. A mechanism proposed is type I hypersensitivity (i.e., I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff339813a34daee1822c1fe92408594
https://doi.org/10.1101/2023.04.11.23288372
https://doi.org/10.1101/2023.04.11.23288372
Autor:
Margaret M Cortese, Allan W Taylor, Lara J Akinbami, Andrea Thames-Allen, Anna R Yousaf, Angela P Campbell, Susan A Maloney, Theresa A Harrington, E Gloria Anyalechi, Datta Munshi, Satoshi Kamidani, C Robinette Curtis, David W McCormick, Mary A Staat, Kathryn M Edwards, C Buddy Creech, Oidda Museru, Paige Marquez, Deborah Thompson, John R Su, Elizabeth P Schlaudecker, Karen R Broder
Publikováno v:
The Journal of Infectious Diseases.
Multisystem inflammatory syndrome in children (MIS-C) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; in the United States, reporting of MIS-C after coronavirus disease 2019 (COVID-19) vaccination is requi
Publikováno v:
The Journal of infectious diseases. 226(Suppl 4)
Background The VARIVAX® Pregnancy Registry was established in 1995 to monitor pregnancy outcomes of women who received varicella vaccine (ie, VARIVAX) inadvertently while pregnant. Methods Health care providers and consumers sent voluntary reports a
Autor:
Lauri E. Markowitz, Gayle E Langley, Heather M. Scobie, Melinda Wharton, Megan J. Wallace, Julia W. Gargano, Tom T. Shimabukuro, Karen R. Broder, Stephen C. Hadler, H. Keipp Talbot, Matthew F. Daley, Julianne Gee, Sara E. Oliver, Eric Weintraub, John R. Su, Danielle Moulia, Matthew E. Oster, Veronica V. McNally, Jose R. Romero, Grace M. Lee
Publikováno v:
Morbidity and Mortality Weekly Report
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine,† and the Advisory Committee on Immunization Practi
Autor:
John R. Su, Julianne Gee, Manette T. Niu, Diane Gubernot, Tom T. Shimabukuro, Pedro L. Moro, Theresa Harrington, Steven A. Anderson, Michael M. McNeil, Sarah D. Bennett, Christine K. Olson, Amelia Jazwa, Richard A. Forshee, Jane Baumblatt, Jonathan Duffy, Satoshi Kamidani, Karen R. Broder, Lakshmi Panagiotakopoulos
Publikováno v:
Vaccine. 39:3666-3677
The Coronavirus Disease 2019 (COVID-19) pandemic has had a devastating impact on global health, and has resulted in an unprecedented, international collaborative effort to develop vaccines to control the outbreak, protect human lives, and avoid furth
Autor:
Ian Kracalik, Matthew E Oster, Karen R Broder, Margaret M Cortese, Maleeka Glover, Karen Shields, C Buddy Creech, Brittney Romanson, Shannon Novosad, Jonathan Soslow, Emmanuel B Walter, Paige Marquez, Jeffrey M Dendy, Jared Woo, Amy L Valderrama, Alejandra Ramirez-Cardenas, Agape Assefa, M Jay Campbell, John R Su, Shelley S Magill, David K Shay, Tom T Shimabukuro, Sridhar V Basavaraju, Paula Campbell, Chidera Anugwom, Colenda Arvelo Jefferson, Kimberly Badger, Nastocia Bafford, Chandra Barnes, Stephanie Boles, Emory Collins, Mitesh Desai, Theresa Dulski, Barbara Dyleski, Kathryn Edwards, Melanie Feyereisen, Stephanie Gonsahn, Tchernavia Gregory, Jyothi Gunta, Kara Jacobs Slifka, Charlotte Kabore, Bryan K. Kapella, Susan Karol, Kalah Kennebrew, Nancy Kluisza, Sean Lang, Labretta Lanier Gholston, Marcella Law, Jennifer Lehman, Jacek M. Mazurek, Henraya McGruder, Kiara McNamara, Maria-Luisa Moore, Pedro Moro, John F. Moroney, Oidda Museru, Cassandra Nale, Andi Neiman, Kim Newsome, Erika Odom, Brooke Pantazides, Suchita Patel, Agam Rao, Laura Reynolds, Sonya Robinson, Frederick L. Ruberg, Tammy Schaeffer, Dipesh Solanky, Laurence Sperling, Toscha Stanley, Regina Sullivan, Allan Taylor, Kimberly Thomas, Shayle Thompson, Jigsa Tola, Cuc H. Tran, Steven Wiersma, Kimberly Works
Publikováno v:
The Lancet. Childadolescent health. 6(11)
Data on medium-term outcomes in indivduals with myocarditis after mRNA COVID-19 vaccination are scarce. We aimed to assess clinical outcomes and quality of life at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescent
Autor:
Jose R. Romero, Amy Blain, Grace M. Lee, Danielle Moulia, Heather M. Scobie, Julia W. Gargano, Megan J. Wallace, Alice Guh, Veronica V. McNally, Jessica R. MacNeil, Stephen C. Hadler, John R. Su, Beth P. Bell, Matthew F. Daley, Sara E. Oliver, H. Keipp Talbot, Karen R. Broder
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 70:651-656
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson; New Brunswick, New J
Autor:
Andrew G. Sokolow, Amy P. Stallings, Carolyn Kercsmar, Theresa Harrington, Natalia Jimenez-Truque, Yuwei Zhu, Katherine Sokolow, M. Anthony Moody, Elizabeth P. Schlaudecker, Emmanuel B. Walter, Mary Allen Staat, Karen R. Broder, C. Buddy Creech
Publikováno v:
Pediatrics. 149(4)
BACKGROUND AND OBJECTIVES Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma